Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference
SGMTSAN MATEO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that it will be presenting a poster at the upcoming 10th Annual MASH-TAG Conference being held January 8-10, 2026 in Park City, Utah. The poster will focus on the observed anti-fibrotic effects in F3 and qFibrosis stage 4 MASH patients in the Phase 2b FASCINATE-2 clinical trial of fatty acid synthase (FASN) inhibitor denifanstat.
Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration
SGMTSAN MATEO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that Ascletis Pharma Inc. issued a December 10 statement that China’s National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for denifanstat for the treatment of moderate to severe acne. Sagimet has granted an exclusive license to denifanstat for China to Ascletis Bioscience Co. Ltd. (Ascletis), of which Ascletis Pharma Inc. is the parent company.
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
SGMTSAN MATEO, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in two upcoming investor conferences.
Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
SGMTDenifanstat met all primary and secondary endpoints in Phase 3 clinical trial in moderate to severe acne conducted by license partner Ascletis in China
Sagimet Biosciences Reported Denifanstat Met All Primary And Secondary Endpoints In A Phase 3 Clinical Trial For The Treatment Of Moderate To Severe Acne Vulgaris Conducted By Sagimet's License Partner Ascletis Bioscience Co. Ltd. (Ascletis) In China
SGMTReported Earlier, Ascletis' Denifanstat, Licensed From Sagimet, Meets All Endpoints In Phase III Trial For Moderate To Severe Acne
SGMTSagimet Biosciences Q1 2025 EPS $(0.56) Beats $(0.65) Estimate, Cash, Cash Equivalents And Marketable Securities As Of March 31, 2025, Were $144.6M
SGMTHC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Announces $32 Price Target
SGMTSagimet Biosciences Q4 2024 GAAP EPS $(0.50) Beats $(0.60) Estimate
SGMTHC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $32 Price Target
SGMTSagimet Biosciences Announces Clearance Of IND For Its FASN Inhibitor TVB-3567 For Acne Treatment
SGMTSagimet Biosciences Announces Oral Presentation At The MASH Pathogenesis And Therapeutic Approaches Keystone Symposium February 23-26, 2025 In Banff, Canada
SGMTSagimet Biosciences Presents Clinical Denifanstat And Preclinical FASN Inhibitor Data At AASLD The Liver Meeting 2024
SGMTHC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $32 Price Target
SGMTSagimet Biosciences Q3 EPS $(0.45) Misses $(0.42) Estimate
SGMTHC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $32 Price Target
SGMTSagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024
SGMTGoldman Sachs Maintains Buy on Sagimet Biosciences, Lowers Price Target to $23
SGMTHC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $32 Price Target
SGMT